Skip navigation

State-by-State Requirements and Reporting ● Current and Future Policy Initiatives ● Operational Best Practices

March 24-25, 2020
  • Philadelphia, PA

Join CBI’s 6th Edition Drug Pricing Transparency Congress, to gather with industry stakeholders to forecast how drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Recent federal and state rulings continue to create lingering questions around legislation and compliance complexities that impact the market in real-time. This uncertainty, in addition to the recent HHS proposal to eliminate rebates, the final ruling on DTC advertisements regarding list prices and the Senate Finance hearing with Pharma CEOs, emphasizes a heightened focus on drug pricing transparency in the United States. Assess the legislative landscape entering into 2020, share best practices for implementation and dive into new state transparency laws to date.

Don’t miss this timely update on state transparency laws — register today!

Previous Attendee Acclaim:

CBI’s Drug Pricing conference helps you keep up to the
date on the latest developments in drug pricing.

Vice President & Assistant General Counsel, Pfizer

Informative discussions to help industry prepare for implementation of the new regulations applicable
to the pharmaceutical industry.

Director, Ethics & Compliance, Novo Nordisk

Very informative – nice location – great speakers
as well with really good presentations.

Anonymous

6th Edition Drug Pricing Transparency Congress

State-by-State Requirements and Reporting ● Current and Future Policy Initiatives ● Operational Best Practices

Join CBI’s 6th Edition Drug Pricing Transparency Congress, to gather with industry stakeholders to forecast how drug pricing transparency regulations will impact commercialization, reimbursement, pricing and compliance practices. Recent federal and state rulings continue to create lingering questions around legislation and compliance complexities that impact the market in real-time. This uncertainty, in addition to the recent HHS proposal to eliminate rebates, the final ruling on DTC advertisements regarding list prices and the Senate Finance hearing with Pharma CEOs, emphasizes a heightened focus on drug pricing transparency in the United States. Assess the legislative landscape entering into 2020, share best practices for implementation and dive into new state transparency laws to date.

Don’t miss this timely update on state transparency laws — register today!

Previous Attendee Acclaim:

CBI’s Drug Pricing conference helps you keep up to the
date on the latest developments in drug pricing.

Vice President & Assistant General Counsel, Pfizer

Informative discussions to help industry prepare for implementation of the new regulations applicable
to the pharmaceutical industry.

Director, Ethics & Compliance, Novo Nordisk

Very informative – nice location – great speakers
as well with really good presentations.

Anonymous